Psoriasis and cardiovascular disorders

Giornale Italiano di Dermatologia e Venereologia

Volumn 147, Issue 2, 2012, Pages 179-187

  Ryan, C ^a   Menter, A ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Briakinumab; Cardiovascular diseases; Methotrexate; Psoriasis; Ustekinumab

Indexed keywords

ADIPONECTIN; BRIAKINUMAB; ETANERCEPT; LEPTIN; METHOTREXATE; ONERCEPT; PLACEBO; RETINOL BINDING PROTEIN 4; USTEKINUMAB;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CIGARETTE SMOKING; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; METABOLIC SYNDROME X; OBESITY; PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84861318155     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Tobin AM, Hughes R, Hand EB, Leong T, Graham IM, Kirby B. Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case-control study. Clin Exp Dermatol 2011;36:19-23.
2. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41. (Pubitemid 44547793)
3. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;555:829-35. (Pubitemid 44556851)
4. Menter A, Griffiths CE, Tebbey PW, Horn EJ, Sterry W, Council IP. Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol 2010;24:1371-7.
5. McDonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med 1973;288:912.
6. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-9. (Pubitemid 350277763)
7. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008;159:895-902.
8. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009;160:1048-56.
9. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-30. (Pubitemid 38461682)
10. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999;135:1490-3.
11. Gisondi P, Fantin F, Del Giglio M, Valbusa F, Marino F, Zamboni M et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology. 2009;218:110-3.
12. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007;156:271-6. (Pubitemid 46095954)
13. Stem RS, Huibregtse A. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J Invest Dermatol 2011;131:1159-66.
14. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 2010;130:962-7.
15. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-6.
16. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010;23:114-8.
17. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007;167:1670-5. (Pubitemid 47280349)
18. Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006;54:614-21.
19. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527-34. (Pubitemid 41815842)
20. Higa-Sansone G, Szomstein S, Soto F, Brasecsco O, Cohen C, Rosenthal RJ. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg 2004;14:1132-4. (Pubitemid 39299743)
21. Wolters M. Diet and psoriasis: experimental data and clinical evidence. Br J Dermatol 2005;153:706-14. (Pubitemid 41415895)
22. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32. (Pubitemid 24365442)
23. Tartaglia LA. The leptin receptor. J Biol Chem 1997;272:6093-6. (Pubitemid 27118072)
24. Bouloumié A, Drexler HC, Lafontan M, Busse R. Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 1998;83:1059-66. (Pubitemid 28520935)
25. Frank S, Stallmeyer B, Kämpfer H, Kolb N, Pfeilschifter J. Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. J Clin Invest 2000;106:501-9. (Pubitemid 30666383)
26. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 2006;67:768-73. (Pubitemid 44062144)
27. Trayhurn P. The biology of obesity. Proc Nutr Soc 2005;64:31-8. (Pubitemid 40685749)
28. Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen HD. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008;158:1134-5. (Pubitemid 351521426)
29. Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008;144:1571-5.
30. Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol. Aug 2008;159:342-50. (Pubitemid 352009847)
31. Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbasi MO, Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008;159:820-6.
32. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93(11 Suppl 1):S64-73.
33. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004;316:924-9. (Pubitemid 38368041)
34. Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361:226-8. (Pubitemid 36126226)
35. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006;110:267-78. (Pubitemid 43341630)
36. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002;277:37487-91.
37. Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008;159:1364-7.
38. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci 2009;55:202-4.
39. Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 2009;55:62-63.
40. Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008;159:1207-8.
41. Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006;49:744-7. (Pubitemid 43357549)
42. Filková M, Haluzík M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 2009;133:157-70.
43. Chu S, Ding W, Li K, Pang Y, Tang C. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 2008;72:1249-53.
44. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-9. (Pubitemid 40279897)
45. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007;157:1249-51. (Pubitemid 350115673)
46. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58. (Pubitemid 46154646)
47. Koczan D, Guthke R, Thiesen HJ, Ibrahim SM, Kundt G, Krentz H et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol. 2005 Jul-Aug 2005;15:251-7.
48. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-62. (Pubitemid 41065039)
49. Rollman O, Vahlquist A. Psoriasis and vitamin A. Plasma transport and skin content of retinol, dehydroretinol and carotenoids in adult patients versus healthy controls. Arch Dermatol Res 1985;278:17-24. (Pubitemid 16235958)
50. Davidovici BB, Sattar N, Prinz JC, Puig L, Emery P, Barker JN et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010;130:1785-96.
51. Sumarac-Dumanovic M, Stevanovic D, Ljubic A, Jorga J, Simic M, Stamenkovic-Pejkovic D et al. Increased activity of interleukin-23/interleukin- 17 proinflammatory axis in obese women. Int J Obes (Lond) 2009;33:151-6.
52. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28. (Pubitemid 40523737)
53. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-8.
54. Grundy SM, Brewer HB, Cleeman JI, Smith SC Jr, Lenfant C; National Heart, Lung, and Blood Institute; American Heart Association. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8. (Pubitemid 38133916)
55. Hulthe J, Hultén LM, Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 2003;52:1612-4. (Pubitemid 38049281)
56. Behnam SM, Behnam SE, Koo JY. Smoking and psoriasis. Skinmed 2005;4:174-6.
57. Torii K, Saito C, Furuhashi T, Nishioka A, Shintani Y, Kawashima K et al. Tobacco smoke is related to Th17 generation with clinical implications for psoriasis patients. Exp Dermatol 2011;20:371-3.
58. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011;20:303-7.
59. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011;12:204-12.
60. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317-25.
61. Ribatti D, Levi-Schaffer F, Kovanen PT. Inflammatory angiogenesis in atherogenesis - a double-edged sword. Ann Med 2008;40:606-21.
62. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995;92:3893-7.
63. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999;145:33-43. (Pubitemid 29292698)
64. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010;130:1373-83.
65. Hauer AD, Uyttenhove C, de Vos P, Stroobant V, Renauld JC, van Berkel TJ et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 2005;112:1054-62. (Pubitemid 41174584)
66. Davenport P, Tipping PG The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003;163:1117-25. (Pubitemid 37040147)
67. Wyss CA, Neidhart M, Altwegg L, Spanaus KS, Yonekawa K, Wischnewsky MB et al. Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. Eur Heart J 2010;31:1457-69.
68. Zhou RH, Shi Q, Gao HQ, Shen BJ. Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J Atheroscler Thromb 2001;8:30-2.
69. Uyemura K, Demer LL, Castle SC, Jullien D, Berliner JA, Gately MK et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996;97:2130-8. (Pubitemid 26143968)
70. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006;17:699-706. (Pubitemid 44934702)
71. Wang Z, Lee J, Zhang Y, Wang H, Liu X, Shang F et al. Increased Th17 cells in coronary artery disease are associated with neutrophilic inflammation. Scand Cardiovasc J 2011;45:54-61.
72. Cheng X, Yu X, Ding YJ, Fu QQ, Xie JJ, Tang TT et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008;127:89-97.
73. Chen S, Crother TR, Arditi M. Emerging role of IL-17 in atherosclerosis. J Innate Immun 2010;2:325-33.
74. Xie JJ, Wang J, Tang TT, Chen J, Gao XL, Yuan J et al. The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice. Cytokine 2010;49:185-.
75. Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, Gallo A et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation. Mar 2009;119:1424-32.
76. Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009;206:2067-77.
77. Wang M, Zhang W, Crisostomo P, Markel T, Meldrum KK, Fu XY et al. Endothelial STAT3 plays a critical role in generalized myocardial proinflammatory and proapoptotic signaling. Am J Physiol Heart Circ Physiol 2007;293:H2101-2108. (Pubitemid 47605851)
78. Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 2006;27:2530-7. (Pubitemid 44627295)
79. Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis. Apr 2008;197:829-39. (Pubitemid 351417882)
80. Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009;35:313-24.
81. Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet function in cutaneous diseases. Platelets 2008;19:317-21.
82. Hayashi S, Shimizu I, Miyauchi H, Watanabe S. Increased platelet aggregation in psoriasis. Acta Derm Venereol 1985;65:258-62. (Pubitemid 15059102)
83. Ludwig RJ, Schultz JE, Boehncke WH, Podda M, Tandi C, Krombach F et al. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol 2004;122:830-6. (Pubitemid 38471355)
84. Tamagawa-Mineoka R, Katoh N, Kishimoto S. Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. J Am Acad Dermatol 2010;62:621-6.
85. Nielsen HJ, Christensen IJ, Svendsen MN, Hansen U, Werther K, Brünner N et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 2002;51:563-7. (Pubitemid 36009183)
86. Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010;24:789-96.
87. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-6. (Pubitemid 24256627)
88. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001;81:335-47. (Pubitemid 32245066)
89. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52:262-7.
90. Boehncke S, Fichtischerer S, Salgo R, Garbaraviciene J, Beschmann H, Diehl S et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res 2011;303:381-8.
91. Boehncke S, Salgo R, Garbaraviciene J, Beschmann H, Hardt K, Diehl S et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol. Jan 2011;25:1187-93.
92. Wu J, Fisher A, Poon K, Burchette R, Shen A. The effect of tumor necrosis factor-alpha inhibitors on the risk of myocardial infarction in patients with psoriasis. Annual Meeting of the American Academy of Dermatology. New Orleans, Louisiana; 2011.
93. Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008;159:322-30. (Pubitemid 352009830)
94. Kanelleas A, Liapi C, Katoulis A, Stavropoulos P, Avgerinou G, Georgala S et al. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol 2011;36:845-50.
95. Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007;56:831-9. (Pubitemid 46399431)
96. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y etal. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74. (Pubitemid 351671883)
97. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84. (Pubitemid 351671884)
98. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92. (Pubitemid 46220818)
99. Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011;63:154-63.
100. Igarashi A, Kato T, Kato M, Nakagawa H. A randomized, double-blind, placebo-controlled study of ustekinumab in Japanese patients with moderate to severe plaque psoriasis [abstract]. Eastern Asia Dermatology Congress, Fukuoka, 〈country-region〉Japan〈/country-region〉2010.
101. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J; ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-7. (Pubitemid 351287002)
102. Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011;165:661-8.
103. Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. May 2011;165:652-60.
104. Gordon K, Langley R, Gottlieb A, Papp KA, Krueger GG, Strober BE et al. A phase III, randomized controlled trial of the fully human IL-12/23 monoclonal antibody, briakinumab, in moderate-to-severe psoriasis. Journal of Investigative Dermatology 2012;132:304-14.
105. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011;306:864-71.